XBRANE
Live / Registered — Registered — partial invalidation of extension of protection (as of 21 Feb 2026)
What this means for you
Registered since 10 Mar 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79253207
- Registration number
- 6004520
- Mark type
- Word mark
- Filed
- 12 Nov 2018
- Published for opposition
- 24 Dec 2019
- Registered
- 10 Mar 2020
- Attorney of record
- Andy I. Corea
Goods and services
- Class 005 — Pharmaceuticals: [ Pharmaceutical preparations and medical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases, ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions and infectious diseases; generic pharmaceutical preparations and biological pharmaceutical preparations all for treating ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis, bone metastasis; chemotherapeutics; hormones for medical purposes; pharmaceutical agents for treating metabolic disorders; amino acids for medical purposes; pharmaceutical agents for treating immunity disorders; pharmaceutical agents for treating physically caused lesions; antiviral preparations; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of cancer, endometriosis, myoma, eye diseases, age related macular degeneration, skin diseases, precocious puberty, vascular diseases, cardiovascular diseases and disorders, oncological diseases and disorders, immune diseases and disorders, autoimmune diseases, angiogenesis diseases and disorders, genetic conditions, infectious diseases; diagnostic kits consisting primarily of monoclonal antibodies for the diagnosis, treatment and prevention of ocular diseases and disorders, inflammatory diseases and disorders, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, diabetes, diabetic macular edema, diabetic related retinopathy, multiple sclerosis, arthritis, osteoporosis and bone metastasis ]
- Class 010 — Medical apparatus: [ Surgical apparatus and instruments; injection device for pharmaceuticals; injection syringes; injection needles; medical apparatus, namely, automatic infusion and injection devices for administering drugs to humans ]
- Class 042 — Scientific and technological services: Scientific and medical research and development; pharmaceutical research and development services; research and development services in the fields of biological similar pharmaceuticals, generic drugs, biotechnology, diagnostics and pharmaceuticals; consultancy services relating to the discovery and evaluation of drugs and chemical compounds having diagnostic properties and therapeutic properties; technical support services, namely, troubleshooting in the nature of diagnosing problems with medical equipment; diagnostic services in the field of troubleshooting biotechnology and pharmaceutical equipment for scientific research purposes; analyzing biotechnology and pharmaceutical equipment for scientific research purposes; development of new technology for others in the field of biotechnology; medical, pharmaceutical and biotechnological laboratory research services; information, consultancy and advisory services relating to scientific and medical research and development, biotechnological and pharmaceutical research and development and medical equipment research and development
Owner
- Xbrane Biopharma AB, SOLNA, SE
- Xbrane Biopharma AB, SE
- Xbrane Biopharma AB, SE
Prosecution history
- 21 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 21 Feb 2026 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 09 Feb 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 03 Oct 2025 — TEAS SECTION 71 RECEIVED
- 10 Mar 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 31 Jul 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 11 Jul 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 11 Jul 2020 — FINAL DISPOSITION PROCESSED
- 10 Jun 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Mar 2020 — REGISTERED-PRINCIPAL REGISTER
- 03 Jan 2020 — NOTIFICATION PROCESSED BY IB
- 24 Dec 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Dec 2019 — PUBLISHED FOR OPPOSITION
- 18 Dec 2019 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 18 Dec 2019 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB